Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of February 2023, with a report date of February 27, 2023. The filing primarily discloses a definitive stock purchase agreement entered into on February 23, 2023, involving the sale of a partial interest in a subsidiary and a strategic partnership with Jeffs' Brands Ltd.
Key Financial Metrics and Transaction Terms
The filing details a specific transaction rather than providing a full set of financial statements for the period. Key financial terms include:
- Transaction Value: $2.5 million in cash for a 49% interest in SciSparc Nutraceuticals Inc. (owner of the Wellution brand).
- Price Adjustments: Expected increase of approximately $300,000 based on inventory and working capital adjustments.
- Consulting Fees: Jeffs' Brands will receive a monthly fee of $20,000 for management services and a one-time signing bonus of $51,000.
- Share Exchange: A reciprocal share exchange valued at $300,000 between SciSparc and Jeffs' Brands, capped at 4.99% beneficial ownership for each party.
The filing text does not provide clear values for overall company revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the divestiture of a 49% equity stake in the Wellution subsidiary. Following the closing, SciSparc will retain a 51% controlling interest. Additionally, the company announced a collaboration with Clearmind regarding future psychedelic-based compounds on February 22, 2023.
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary conditions and is expected to close within seven business days of the effective date (February 23, 2023).
Consulting Agreement: The management services agreement is for an undefined period and may be terminated by either party with 30 days' advance notice.
Securities Restrictions: The shares issued in the transaction are not registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or an applicable exemption.
Disclaimer: The filing explicitly states that representations and warranties in the agreement are for the benefit of the parties only and should not be relied upon as characterizations of the actual state of facts.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $2.5 million cash receipt plus adjustments.
- Confirm the final number of shares issued in the reciprocal exchange based on the 30-day average closing price.
- Review the specific terms of the consulting agreement regarding the $20,000 monthly fee and termination rights.
- Assess the impact of retaining only 51% of the Wellution subsidiary on future consolidated revenue recognition.
- Investigate the status and potential commercialization timeline of the psychedelic-based compounds announced with Clearmind.